Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia (FAST)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02611973 |
|
Recruitment Status :
Recruiting
First Posted : November 23, 2015
Last Update Posted : July 26, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The hypothesis is that efficient prevention of thrombosis with aspirin at diagnosis becomes less useful once patients have achieved a hematologic response (HR) (modified by amendment 1/03/2017) and/or that this benefit is hampered by an increased hemorrhagic risk especially in elderly patients.
Hence, investigator propose a prospective randomized study to assess the benefit / risk ratio of aspirin maintenance in high risk Essential thrombocythemia (ET) patients, in hematological response (modified by amendment 1/03/2017) on Hydroxyurea.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| MPN Essential Thrombocythemia | Other: Aspirin therapy interruption Other: Usual treatment by aspirin 100 mg/d in the active comparator arm Other: No interruption of aspirin in the Observational arm Drug: Hydroxyurea treatment (HU) | Phase 3 |
ET is a myeloproliferative neoplasm (MPN) characterized by a high platelet level. Increased occurrence of thrombosis and hemorrhages are the main complications in ET. In this regard, the key factors defining high risk ET include age over 60 years, past history of thrombosis, platelet > 1500 109/L and to a lesser degree cardiovascular risk factors. These criteria currently serve as therapeutic guidelines for the use of cytoreductive therapy, with hydroxyurea (HU) being the treatment of choice in the first line setting.
The use of antiplatelet agent i.e. low-dose aspirin is also generally recommended. However, the benefit of aspirin has never been formally demonstrated in ET. Only indirect evidence come from the ECLAP study that enrolled patients with polycythemia vera (PV). Of note in the ECLAP study, the efficacy of aspirin was assessed only at diagnosis but not correlated thereafter with the hematological response on cytoreductive therapy.
In general non-MPN population studies, primary prophylaxis with aspirin has been associated with a risk reduction of major vascular events, but an increased risk of hemorrhage, especially considering age and prior gastrointestinal history. In a recent retrospective study, the combination of aspirin and cytoreduction was reported to prevent thrombosis but concomitantly increase the bleeding risk when compared to HU alone , especially in patients older than 60 years, thus questioning the benefits of long term use of aspirin therapy. These data raise the question of the actual benefit of aspirin maintenance, once patients have been efficiently treated with cytoreductive therapy.
Hence, investigator propose a prospective randomized study to assess the benefit / risk ratio of aspirin maintenance in high risk ET patients, in hematological response (modified by amendment 1/03/2017) on Hydroxyurea. Patients for which Aspirin interruption will not be possible because of extra-ET indications will be enrolled in the control observational arm.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 2250 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study |
| Actual Study Start Date : | March 10, 2016 |
| Estimated Primary Completion Date : | November 2019 |
| Estimated Study Completion Date : | November 2022 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: HU without aspirin |
Other: Aspirin therapy interruption
Stop the treatment by aspirin 100mg/d in the experimental arm. Drug: Hydroxyurea treatment (HU) HU maintenance |
| Active Comparator: HU + aspirin maintenance |
Other: Usual treatment by aspirin 100 mg/d in the active comparator arm
HU+ aspirin maintenance Drug: Hydroxyurea treatment (HU) HU maintenance |
|
HU + AAG
Observational arm
|
Other: No interruption of aspirin in the Observational arm
patient with Contre indication to aspirin or required antithrombotic therapy Drug: Hydroxyurea treatment (HU) HU maintenance |
- Cumulative incidence of death from vascular origin and other thrombotic and hemorrhagic events (combined endpoint) [ Time Frame: at 2-years follow-up ]
Definition of vascular events:
Thrombotic events: Myocardial infarction, unstable angina, stroke, transient ischemic attack, peripheral arterial thrombosis, splanchnic or limb deep vein thrombosis, pulmonary embolism, and erythromelalgia
Hemorrhagic events:
Intracranial or retroperitoneal bleed, overt hemorrhage associated with a decrease in hemoglobin ≥20 g/l or overt hemorrhage requiring a blood transfusion of two red blood cell (RBC) units or more, and hemorrhage of grade >=2 according to the NCI Common Toxicity criteria (CTC) V.4.0 scale.
Deaths will be included as a death from thrombosis or hemorrhage if they satisfied criteria for one of the above diagnoses immediately ANTE-MORTEM or if they had a POST-MORTEM examination confirming the diagnosis. Sudden death of presumed vascular origin without a POST-MORTEM examination will be included as a thrombotic death.
- Cumulative incidence and characteristics of vascular complications: thrombosis and hemorrhage, (grade, site, recurrence), assessed yearly over a 5-year follow-up period. [ Time Frame: at 5 years ]
- Rate of hematological response every 6 months [ Time Frame: at 5 years ]Hematological response as assessed by European Leukemia Net (ELN) criteria, revised ELN International Working Group on Myeloproliferative Neoplasms Research and Treatment (ELN -IWG MRT).
- Adverse event (AE) frequency and incidence, comparison in the two arms [ Time Frame: at 5 years ]
- Number of HU-related nonhematologic toxicities [ Time Frame: at 5 years ]
- Cumulative incidence of thrombosis [ Time Frame: at 5 years ]
- Cumulative incidence of hemorrhagic complications [ Time Frame: at 5 years ]
- Estimation of the progression-free survival [ Time Frame: at 5 years ]
- Estimation of overall survival [ Time Frame: at 5 years ]
- Short Form 36 (SF36) Health Survey [ Time Frame: through study completion, an average of 1 year ]Evaluation of quality of life by using SF36
- Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) [ Time Frame: through study completion, an average of 1 year ]Evaluation of quality of life by using (MPN-SAF)
- Number of mortality cause. [ Time Frame: at 5 years ]
- Cumulative incidence of progression to polyglobulia [ Time Frame: at 5 years ]
- Cumulative incidence of progression to myelofibrosis (MF) [ Time Frame: at 5 years ]
- Cumulative incidence of progression to myelodysplastic syndrome (MDS) [ Time Frame: at 5 years ]
- Cumulative incidence of progression AML [ Time Frame: at 5 years ]
- Frequencies of mutations (JAK2V617F, MPLw515 and CALR) and JAK2V617F allele burden, MPLw515 allele burden and CALR mutation allele burden (in blood DNA) in patients presenting thrombosis or not . [ Time Frame: at 5 years ]
- Frequencies of mutations (JAK2V617F, MPLw515 and CALR) and JAK2V617F allele burden, MPLw515 allele burden and CALR mutation allele burden in patients in persistent hematological response (modified by amendment 1/03/2017). [ Time Frame: at 5 years ]responses and intolerance define according to ELN criteria
- Frequencies of mutations (JAK2V617F, MPLw515 and CALR) and JAK2V617F allele burden, MPLw515 allele burden and CALR mutation allele burden in patient who will lose their hematological response (modified by amendment 1/03/2017). [ Time Frame: at 5 years ]responses and intolerance define according to ELN criteria
- Frequencies of mutations (JAK2V617F, MPLw515 and CALR) and JAK2V617F allele burden, MPLw515 allele burden and CALR mutation allele burden in patients presenting intolerance to treatment. [ Time Frame: at 5 years ]responses and intolerance define according to ELN criteria
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- > 18 years and older (modified by amendment 01/03/2017)
-
Contraception considered effective by the investigator: for women of childbearing and for men whose partner is likely to procreate (added by amendment 01/03/2017)
- Diagnosis of ET performed within the last 10 years (modified by amendment 01/03/2017) : with or without Janus kinase 2V617F (JAK2V617F) mutation according to the WHO 2008 criteria (TEFFERI,2007)
- ET patients currently treated with hydroxyurea in first line, who have achieved a complete or partial hematologic response according to the ELN 2009 (BAROSI, 2009) modified (at least three month apart and at inclusion) (modified by amendment 01/03/2017)
- Signed Written Informed Consent
- Health insurance coverage.
Exclusion Criteria:
- Other myeloproliferative disorder than ET.
- Contra-indication to hydroxyurea.
- Other uncontrolled malignancies at the time of diagnosis or inclusion.
-
History of haemostasis perturbation not related to ET, associated with a significant risk of hemorrhage or thrombosis (modified by amendment 01/03/2017)
-.• Pregnancy or breastfeeding (added by amendment 01/03/2017)
- Inability to freely provide consent through judiciary or administrative condition.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02611973
| Contact: Stéphane Giraudier, MD, PhD | (0)149812880 ext +33 | stephane.giraudier@aphp.fr |
| France | |
| Henri Mondor Hospital | Recruiting |
| Creteil, France, 94010 | |
| Contact: Stéphane Giraudier, MD, PhD (0)149812880 ext +33 stephane.giraudier@aphp.fr | |
| Contact: Onja Rarison, CRA (0)149813387 ext +33 onja.rarison@aphp.fr | |
| Principal Investigator: | Stéphane Giraudier, MD, PhD | Assistance Publique - Hôpitaux de Paris |
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT02611973 |
| Other Study ID Numbers: |
P140933 |
| First Posted: | November 23, 2015 Key Record Dates |
| Last Update Posted: | July 26, 2017 |
| Last Verified: | July 2017 |
|
Essential Thrombocythemia Aspirin |
|
Thrombocytosis Thrombocythemia, Essential Blood Platelet Disorders Hematologic Diseases Myeloproliferative Disorders Bone Marrow Diseases Blood Coagulation Disorders Hemorrhagic Disorders Aspirin Hydroxyurea Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Antineoplastic Agents Antisickling Agents Nucleic Acid Synthesis Inhibitors |